{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:44:25Z","timestamp":1791837865601,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clim.2026.110781","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:10:23Z","timestamp":1791151823000},"page":"110781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of bi-functional hybrid IgGA antibodies for enhancing cancer immunotherapy"],"prefix":"10.1016","volume":"288","author":[{"given":"Xiuyun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav","family":"Rybchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naida","family":"Mamaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Dolgikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-4708","authenticated-orcid":false,"given":"Victoria","family":"Argentova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110781_bb0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fimmu.2019.00553","article-title":"IgA and Fc\u03b1RI: pathological roles and therapeutic opportunities","volume":"10","author":"Breedveld","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110781_bb0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1040-8428(01)00105-6","article-title":"IgA antibodies for cancer therapy","volume":"39","author":"Dechant","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.clim.2026.110781_bb0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/imcb.12306","article-title":"Serum IgA Fc effector functions in infectious disease and cancer","volume":"98","author":"Davis","year":"2020","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.clim.2026.110781_bb0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fc\u03b3 receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.clim.2026.110781_bb0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"26","author":"Chen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110781_bb0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/immuno2020023","article-title":"Correlation of anti-HLA IgA alloantibodies and Fc receptor motives with kidney allograft survival","volume":"2","author":"Arnold","year":"2022","journal-title":"Immuno"},{"key":"10.1016\/j.clim.2026.110781_bb0035","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3389\/fimmu.2019.00704","article-title":"Potent fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG","volume":"10","author":"Brandsma","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110781_bb0040","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","article-title":"Neutrophils kill antibody-opsonized cancer cells by trogoptosis","volume":"23","author":"Matlung","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.clim.2026.110781_bb0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2006-06-025882","article-title":"IgA Fc receptor I signals apoptosis through the FcR ITAM and affects tumor growth","volume":"109","author":"Kanamaru","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110781_bb0050","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.3390\/ijms21217820","article-title":"The neutrophil: the underdog that packs a punch in the fight against cancer","volume":"21","author":"Avtenyuk","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2026.110781_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.761816","article-title":"IgA complexes induce neutrophil extracellular trap formation more potently than IgG complexes","volume":"12","author":"Gimpel","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110781_bb0060","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/imr.13159","article-title":"Neutrophils as immune effector cells in antibody therapy in cancer","volume":"314","author":"Behrens","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2026.110781_bb0065","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2026.110781_bb0070","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.clim.2026.110781_bb0075","article-title":"Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression","volume":"1316","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110781_bb0080","first-page":"5023","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"12","author":"Wang","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.clim.2026.110781_bb0085","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Sci"},{"key":"10.1016\/j.clim.2026.110781_bb0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.clim.2026.110781_bb0095","doi-asserted-by":"crossref","first-page":"16056","DOI":"10.1021\/bi048233g","article-title":"A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein-protein interactions by fluorescence polarization","volume":"43","author":"Roehrl","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.clim.2026.110781_bb0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chembiol.2014.10.017","article-title":"IgGA: a \u201ccross-isotype\u201d engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions","volume":"21","author":"Kelton","year":"2014","journal-title":"Chem. Biol."},{"issue":"7528","key":"10.1016\/j.clim.2026.110781_bb0105","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:44:31Z","timestamp":1791834271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":21,"alternative-id":["S1521661626001191"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110781","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of bi-functional hybrid IgGA antibodies for enhancing cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110781"}}